This study sought to determine whether statin initiation for the primary prevention of CVD would improve outcomes.
Researchers wanted to compare ticagrelor with clopidogrel in patients with non-ST elevation acute coronary syndrome to fill a gap in the data about the performance of these drugs.
The researchers sought to characterize the relationship between inflammatory markers and baseline, maximum, and change in troponin levels.
Researchers evaluated data on clinical outcomes among 107,000 patients from the National Inpatient Sample who had both cancer and atrial fibrillation.
Elevated troponin-I levels were linked to clinical trajectory in a cohort of hospitalized patients with COVID-19.
Researchers conducted a review of patients who were tested for COVID-19 and received aspirin or NSAIDS to assess whether aspirin was protective from death, myocardial infarction, or VTE.
Researchers aimed to study the associations between heart failure medications and certain systemic autoimmune rheumatic diseases.
No significant difference in rates of cardiovascular death and all-cause mortality was noted.
The researchers sought to identify major interaction effects between clopidogrel and CYP2C19*17 status, in terms of risk for MACE and bleeding events after PCI.
Researchers assessed the results of the VICTORIA trial, which included 5048 patients with worsening heart failure, 53.6% of whom had coronary artery disease.